Reni Benjamin
Stock Analyst at JMP Securities
(2.40)
# 1,499
Out of 4,502 analysts
117
Total ratings
47.58%
Success rate
-3.54%
Average return
Main Sectors:
Top Industries:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx | Initiates: Market Perform | n/a | $13.32 | - | 7 | Jul 23, 2024 | |
| HOWL Werewolf Therapeutics | Reiterates: Market Outperform | $12 | $2.71 | +343.62% | 4 | Jun 26, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Market Outperform | $25 → $23 | $9.18 | +150.68% | 9 | Jun 20, 2024 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $32 | $21.00 | +52.38% | 6 | Jun 18, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $113.67 | +9.97% | 11 | Jun 7, 2024 | |
| BCAB BioAtla | Maintains: Market Outperform | $12 → $5 | $1.64 | +204.88% | 7 | May 23, 2024 | |
| STRO Sutro Biopharma | Reiterates: Market Outperform | $17 | $4.41 | +285.49% | 7 | Apr 3, 2024 | |
| PRLD Prelude Therapeutics | Initiates: Market Outperform | $7 | $5.91 | +18.54% | 1 | Mar 13, 2024 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $8 → $15 | $6.33 | +137.15% | 3 | Mar 1, 2024 | |
| INCY Incyte | Downgrades: Market Perform | n/a | $68.91 | - | 14 | Feb 14, 2024 | |
| ALLO Allogene Therapeutics | Downgrades: Market Perform | n/a | $2.92 | - | 6 | Jan 5, 2024 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $44 → $32 | $24.74 | +29.35% | 10 | Dec 20, 2023 | |
| LVTX LAVA Therapeutics | Reiterates: Market Outperform | $6 | $2.11 | +184.36% | 4 | Aug 23, 2023 | |
| ACET Adicet Bio | Downgrades: Market Perform | n/a | $1.61 | - | 3 | Jun 27, 2023 | |
| CUE Cue Biopharma | Reiterates: Outperform | $15 | $0.67 | +2,122.55% | 2 | May 15, 2023 | |
| EFTR eFFECTOR Therapeutics | Maintains: Market Outperform | $50 → $25 | $0.05 | +54,247.83% | 5 | Jan 9, 2023 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.77 | +125.99% | 1 | Aug 8, 2022 | |
| MGNX MacroGenics | Upgrades: Market Perform | n/a | $5.56 | - | 2 | Feb 7, 2019 | |
| RGNX REGENXBIO | Upgrades: Strong Buy | n/a | $14.33 | - | 2 | Feb 5, 2019 | |
| LPTX Leap Therapeutics | Maintains: Outperform | n/a | $2.20 | - | 2 | Dec 19, 2018 | |
| VYGR Voyager Therapeutics | Upgrades: Strong Buy | n/a | $9.23 | - | 2 | Nov 15, 2018 | |
| ADVM Adverum Biotechnologies | Downgrades: Market Perform | n/a | $7.96 | - | 2 | Nov 2, 2018 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | n/a | $1.35 | - | 1 | Oct 22, 2018 | |
| ADMA ADMA Biologics | Maintains: Outperform | n/a | $13.05 | - | 2 | Oct 12, 2018 | |
| TGTX TG Therapeutics | Downgrades: Outperform | n/a | $20.62 | - | 1 | Sep 25, 2018 | |
| URGN UroGen Pharma | Downgrades: Market Perform | n/a | $16.17 | - | 1 | Nov 15, 2017 | |
| ONVO Organovo Holdings | Downgrades: Market Perform | n/a | $0.58 | - | 1 | Nov 10, 2017 | |
| BOLD Boundless Bio | Initiates: Market Perform | n/a | $3.73 | - | 1 | Oct 12, 2017 |
Inhibrx
Jul 23, 2024
Initiates: Market Perform
Price Target: n/a
Current: $13.32
Upside: -
Werewolf Therapeutics
Jun 26, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $2.71
Upside: +343.62%
Iovance Biotherapeutics
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $9.18
Upside: +150.68%
Kura Oncology
Jun 18, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $21.00
Upside: +52.38%
Blueprint Medicines
Jun 7, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $113.67
Upside: +9.97%
BioAtla
May 23, 2024
Maintains: Market Outperform
Price Target: $12 → $5
Current: $1.64
Upside: +204.88%
Sutro Biopharma
Apr 3, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $4.41
Upside: +285.49%
Prelude Therapeutics
Mar 13, 2024
Initiates: Market Outperform
Price Target: $7
Current: $5.91
Upside: +18.54%
Sana Biotechnology
Mar 1, 2024
Maintains: Market Outperform
Price Target: $8 → $15
Current: $6.33
Upside: +137.15%
Incyte
Feb 14, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $68.91
Upside: -
Allogene Therapeutics
Jan 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.92
Upside: -
Bicycle Therapeutics
Dec 20, 2023
Maintains: Market Outperform
Price Target: $44 → $32
Current: $24.74
Upside: +29.35%
LAVA Therapeutics
Aug 23, 2023
Reiterates: Market Outperform
Price Target: $6
Current: $2.11
Upside: +184.36%
Adicet Bio
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.61
Upside: -
Cue Biopharma
May 15, 2023
Reiterates: Outperform
Price Target: $15
Current: $0.67
Upside: +2,122.55%
eFFECTOR Therapeutics
Jan 9, 2023
Maintains: Market Outperform
Price Target: $50 → $25
Current: $0.05
Upside: +54,247.83%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.77
Upside: +125.99%
MacroGenics
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $5.56
Upside: -
REGENXBIO
Feb 5, 2019
Upgrades: Strong Buy
Price Target: n/a
Current: $14.33
Upside: -
Leap Therapeutics
Dec 19, 2018
Maintains: Outperform
Price Target: n/a
Current: $2.20
Upside: -
Voyager Therapeutics
Nov 15, 2018
Upgrades: Strong Buy
Price Target: n/a
Current: $9.23
Upside: -
Adverum Biotechnologies
Nov 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $7.96
Upside: -
Adaptimmune Therapeutics
Oct 22, 2018
Maintains: Outperform
Price Target: n/a
Current: $1.35
Upside: -
ADMA Biologics
Oct 12, 2018
Maintains: Outperform
Price Target: n/a
Current: $13.05
Upside: -
TG Therapeutics
Sep 25, 2018
Downgrades: Outperform
Price Target: n/a
Current: $20.62
Upside: -
UroGen Pharma
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.17
Upside: -
Organovo Holdings
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $0.58
Upside: -
Boundless Bio
Oct 12, 2017
Initiates: Market Perform
Price Target: n/a
Current: $3.73
Upside: -